Status:

ACTIVE_NOT_RECRUITING

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

Lead Sponsor:

Abramson Cancer Center at Penn Medicine

Collaborating Sponsors:

Loyola University

Oregon Health and Science University

Conditions:

Hepatocellular Carcinoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation. No prospecti...

Detailed Description

The purpose of this study is to determine whether the combination of stereotatic body radiotherapy (SBRT) tand transarterial chemoembolization (TACE) is an effective "bridging therapy" for patients he...

Eligibility Criteria

Inclusion

  • Patient capable of giving informed consent
  • Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed for orthotopic liver transplantation at the participating institution
  • Age \> 18 years old
  • Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
  • Childs' Class A or B7
  • Eastern Clinical Oncology Group performance status 0 or 1

Exclusion

  • Prior radiotherapy to the upper abdomen or radioembolization of the liver
  • Prior TACE to the target lesion, RFA, or liver transplant
  • Active GI bleed within 2 weeks of study enrollment
  • Active GI ulcer disease within 4 weeks of study enrollment
  • Ascites refractory to medical therapy
  • Contraindication to receiving radiotherapy or TACE
  • Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
  • Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
  • Women who are pregnant
  • Participation in another concurrent treatment protocol

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT01918683

Start Date

July 1 2013

End Date

December 1 2027

Last Update

January 28 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Loyola University Medical Center

Maywood, Illinois, United States, 60153

2

Oregon Health & Science University

Portland, Oregon, United States, 97239

3

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | DecenTrialz